COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
1 Months Ended | 6 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Jan. 11, 2022 |
May 14, 2021 |
Jun. 04, 2020 |
May 08, 2020 |
Dec. 10, 2015 |
Feb. 20, 2020 |
May 30, 2019 |
Mar. 28, 2019 |
Jun. 30, 2022 |
Dec. 31, 2021 |
Sep. 30, 2019 |
|
| Renumeration amount | $ 6,000 | ||||||||||
| Consideration amount | $ 657,640 | $ 41,600 | $ 314,600 | $ 894,600 | 10,700 | ||||||
| First payment owed | $ 145,000 | 46,422 | |||||||||
| Attorney's fees | $ 235,886 | ||||||||||
| Monthly amount received common stock equivalent | $ 3,750 | ||||||||||
| Monthly amount received common stock equivalent by consultant | 1,375 | ||||||||||
| Interest rate | 10.00% | ||||||||||
| Stock options grant | 5,000 | ||||||||||
| Consulting services valued | $ 10,751 | ||||||||||
| Compensation for services, description | As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) one consultant shall receive common stock equivalent to $6,667 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month. | ||||||||||
| Monthly remuneration amount | $ 3,500 | ||||||||||
| Option [Member] | |||||||||||
| Stock options description | (i) Company shall grant 10,000 incentive Stock Options upon achievement of U.S. $500,000 collected gross revenues, (ii) Company shall grant 20,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $1,000,000 collected gross revenues, (iii) Company shall grant 30,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $1,500,000 collected gross revenues, (iv) Company shall grant 40,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $2,000,000 collected gross revenues | ||||||||||
| Galligan Subscription and Royalty Agreement [Member] | |||||||||||
| Common stock, Shares issued | 200,000 | ||||||||||
| Subscription and Royalty Agreement | $ 3,000,000 | ||||||||||
| Royality percentage minimum | 10.00% | ||||||||||
| Royality percentage maximum | 15.00% | ||||||||||
| Agreement description | On April 1, 2019, the Company entered into a Subscription and Royalty Agreement (the “Galligan Subscription and Royalty Agreement” and, together with the Lucido Subscription and Royalty Agreement, the “Agreements”) with the J and R Galligan Revocable Trust, managed by Mr. Galligan, a holder of between 10% and 15% of the Company’s shares of common stock and a member of the Company’s Board of Direct | ||||||||||
| Lucido Subscription and Royalty Agreement [Member] | |||||||||||
| Royality percentage minimum | 10.00% | ||||||||||
| Royality percentage maximum | 15.00% | ||||||||||
| Purchase price | $ 15.00 | ||||||||||
| Common stock | 200,000 | ||||||||||
| Revenue per share | $ 37.50 | ||||||||||
| Gross revenue per share | $ 25.00 | ||||||||||
| Percent of aggregate purchase price | 65.00% | ||||||||||
| Development and expansion expenses amount | $ 3,000,000 | ||||||||||
| Subscription and royalty agreement description | Pursuant to the Lucido Subscription and Royalty Agreement: (i) Mr. Lucido purchased shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay Lucido (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”). | ||||||||||
| Description for the use of proceeds under agreement | The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company’s weight loss program (the “Business”) including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. The Company received consent of Mr. Lucido to use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development | ||||||||||
| Alpine Creek [Member] | |||||||||||
| Royalty due | $ 91 | $ 91 | |||||||||
| Total consideration amount | $ 1,531,926 | ||||||||||
| Payables to Alpine Creek | $ 1,215,000 | ||||||||||
| Payable commitment description | Alpine Creek fifty percent (50%) for each Treatment following the Effective Date until the Company has paid Alpine Creek an aggregate of $1,620,000, with the exception of treatments conducted in certain territories | On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale | |||||||||
| Payable per treatment sold | $ 100 | ||||||||||
| Profit holding percentage | 50.00% | ||||||||||
| Lucido [Member] | |||||||||||
| Common stock, Shares issued | 200,000 | ||||||||||
| Charles River Laboratories, Inc. [Member] | |||||||||||
| Consideration amount | $ 3,024,476 | ||||||||||
| Remaining commitment | $ 28,936 | ||||||||||
| BICX Holding Company LLC [Member] | |||||||||||
| Common stock issued upon convertible debt | 2,227,575 | ||||||||||
| Convertible Promissory Note | $ 4,160,000 | ||||||||||
| Conversion agreement description | Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment | ||||||||||
| Issuance price | $ 2.00 | ||||||||||
| Amount due to investor | $ 1,138,157 | ||||||||||
| Minimum [Member] | |||||||||||
| Remuneration amount | 10,000 | ||||||||||
| Maximum [Member] | |||||||||||
| Remuneration amount | $ 12,500 | ||||||||||